Thrombolytic therapy for acute ischemic stroke: 3 h and beyond

Area of Science:

• Neurology
• Radiology
• Pharmacology

Background:

• Current Food and Drug Administration (FDA)-approved thrombolytic therapy for ischemic stroke is intravenous recombinant plasminogen activator (tPA) administered within 3 hours.
• Intra-arterial thrombolysis is an option for up to 6 hours but lacks FDA approval for stroke.
• Emerging imaging techniques reveal a variable time window for effective thrombolysis.

Purpose of the Study:

• To explore the potential for extending the therapeutic time window for ischemic stroke treatment.
• To investigate the role of advanced imaging in identifying salvageable brain tissue.
• To assess the potential impact of neuroprotective agents on reperfusion therapy.

Main Methods:

• Review of current FDA-approved thrombolytic therapies and their limitations.
• Analysis of advanced radiologic methods, including magnetic resonance imaging (MRI) and perfusion computed tomography (CT).
• Consideration of neuroprotective drug development for stroke treatment.

Main Results:

• Advanced imaging suggests that the ischemic penumbra (salvageable brain tissue) may remain viable for extended periods beyond the standard 3-hour window.
• Perfusion imaging demonstrates that the time window for effective thrombolytic therapy is not fixed and can be longer than currently recognized.
• The stability of the ischemic penumbra could be enhanced by neuroprotective agents.

Conclusions:

• Radiologic methods indicate a potentially larger time window for thrombolytic therapy in ischemic stroke.
• Neuroprotective drugs could stabilize the ischemic penumbra, further extending treatment opportunities.
• Further research into advanced imaging and neuroprotection is warranted to optimize stroke reperfusion strategies.